At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 enrolled
Drug / intervention
PF-07321332/ritonavir +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
COVID-19: A PHASE 1, OPEN-LABEL, FIXED SEQUENCE, 2-PERIOD CROSSOVER STUDY TO ESTIMATE THE EFFECT OF ITRACONAZOLE ON THE PHARMACOKINETICS OF PF-07321332/RITONAVIR IN HEALTHY PARTICIPANTS
In Brief
A Phase 1 clinical trial evaluating PF-07321332/ritonavir and Itraconazole for Healthy Participant. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The purpose of this study is to estimate the effect of a strong inhibitor of CYP3A4 (itraconazole) on the pharmacokinetics (PK) of PF-07321332/ritonavir in healthy participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Participant
CountriesBelgium
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedJul 2021
Enrollment StartJul 2021
Primary CompletionSep 2021
TodayJul 2026
First PostedJul 14, 2021
Enrollment StartJul 20, 2021
Primary CompletionSep 30, 2021
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 5.0 years ago
Interventions
PF-07321332/ritonavirdrug
Administered orally every 12 hours for days for a total of 5 doses from Day 1 through Day 3
Itraconazoledrug
Administered orally once daily for 8 days from Days 1 through 8
PF-07321332/ritonavirdrug
Administered orally BID for 3 day for a total on 5 doses starting on Day 4 through Day 6